Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Eric L. Simpson et al.|The Lancet|2021Cited by 538
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune SystemYung‐Tsu Cho, Chia‐Yu Chu|International Journal of Molecular Sciences|2017Cited by 285